890 assets in Neoplasm

Therapeutic assets addressing Neoplasm, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
1H-ISOINDOL-1-ONE, 7-((6-((DIMETHYLAMINO)METHYL)-5-((3S)-TETRAHYDRO-3-FURANYL)-2-PYRIDINYL)AMINO)-4-(7-FLUOROIMIDAZO(1,2-A)PYRIDIN-3-YL)-2,3-DIHYDRO- Neoplasm	Nimbus Saturn, Inc.	P1/2	CC (40)
23me-00610 Neoplasm	23andMe, Inc.	P1/2	CC (40)
23me-01473 Neoplasm	23andMe, Inc.	P1/2	CC (40)
4H-Pyrido[1,2-a]pyrimidine-2-carboxamide, N-[[2-[[(cyclobutylmethyl)amino]methyl]-1H-indol-6-yl]methyl]-4-oxo- Neoplasm	STORM Therapeutics LTD	P1/2	CC (40)
4scar-276 Neoplasm	Shenzhen Geno-Immune Medical Institute	P1/2	CC (40)
7mw3711 Neoplasm	Mabwell (Shanghai) Bioscience Co., Ltd.	P1/2	CC (40)
a2b530 Neoplasm	A2 Biotherapeutics Inc.	P1/2	CC (40)
Afnt-211 Neoplasm	Affini-T Therapeutics, Inc.	P1/2	CC (40)
Alg.Apv-527 Neoplasm	Aptevo Therapeutics	P1/2	CC (40)
Allocetra-Ots Neoplasm	Enlivex Therapeutics RDO Ltd.	P1/2	CC (40)
Allogeneic Natural Killer Cells Neoplasm	Beijing Kejing Biotechnology Co., Ltd.	P1	CC (40)
Allogeneic Tcr-Enhanced Vδ2 T Cell Neoplasm	Chinese PLA General Hospital	P1/2	CC (40)
AS01b Neoplasm	Universitair Ziekenhuis Brussel	P1/2	CC (40)
Ast-001 Neoplasm	Ascentawits Pharmaceuticals, Ltd	P1/2	CC (40)
at-1965 liposome Neoplasm	Alyssum Therapeutics	P1/2	CC (40)
Atamparib Neoplasm	Nerviano Medical Sciences (Shanghai) Ltd.	P1/2	CC (40)
Autologous Rapamycin-Resistant Th1/Tc1 Cells Rapa-201 Neoplasm	Rapa Therapeutics LLC	P1/2	CC (40)
Balstilimab Neoplasm	Rottapharm Biotech	P1/2	CC (40)
bay3547922 Neoplasm	Bayer	P1	CC (40)
bay3630942 Neoplasm	Bayer	P1	CC (40)
Bhv-1510 Neoplasm	Biohaven Therapeutics Ltd.	P1/2	CC (40)
bi-4scar gd2/psma t cells Neoplasm	Shenzhen Geno-Immune Medical Institute	P1/2	CC (40)
bnt141 Neoplasm	BioNTech SE	P1/2	CC (40)
bnt142 Neoplasm	BioNTech SE	P1/2	CC (40)
Bpb-101 Neoplasm	Betta Pharmaceuticals Co., Ltd.	P1/2	CC (40)
Brivestobart Neoplasm	Guangzhou Gloria Biosciences Co., Ltd.	P1/2	CC (40)
c019199 Neoplasm	Fujian Haixi Pharmaceuticals Co., Ltd.	P1/2	CC (40)
[C]-Bi 907828 Mixed With Bi 907828 Neoplasm	Boehringer Ingelheim	P1	CC (40)
Cetrelimab Neoplasm	Johnson & Johnson Enterprise Innovation Inc.	P1	CC (40)
cft1946 Neoplasm	C4 Therapeutics, Inc.	P1	CC (40)
Cmts1215 Oncolytic Bacteria Neoplasm	The Second Hospital of Nanjing Medical University	P1/2	CC (40)
Crb-601 Monoclonal Antibody Neoplasm	Corbus Pharmaceuticals Inc.	P1/2	CC (40)
cts3497 Neoplasm	CytosinLab Therapeutics Co., Ltd.	P1/2	CC (40)
Disialoganglioside Gd-2 Neoplasm	Shenzhen Geno-Immune Medical Institute	P1/2	CC (40)
Donafenib Neoplasm	Suzhou Zelgen Biopharmaceuticals Co.,Ltd	P1/2	CC (40)
Erfonrilimab Neoplasm	Suzhou Kintor Pharmaceutical Inc,	P1/2	CC (40)
Fog-001 Neoplasm	Parabilis Medicines, Inc.	P1/2	CC (40)
Fosdesdenosine Sipalabenamide Neoplasm	NuCana plc	P1/2	CC (40)
Gallium-68 Labelled Fap-2286 Neoplasm	Novartis Pharmaceuticals	P1/2	CC (40)
Garsorasib Neoplasm	InventisBio Co., Ltd	P1/2	CC (40)
gfs101a Neoplasm	Zhejiang Genfleet Therapeutics Co., Ltd.	P1/2	CC (40)
Gim-531 Neoplasm	Georgiamune Inc	P1/2	CC (40)
Gls-010 Neoplasm	Guangzhou Gloria Biosciences Co., Ltd.	P1/2	CC (40)
gsk4418959 Neoplasm	GlaxoSmithKline	P1/2	CC (40)
Hla-G-Car.Bite Allogeneic Γδ T Cells Neoplasm	Ever Supreme Bio Technology Co., Ltd.	P1/2	CC (40)
Hrs-8364 Neoplasm	Jiangsu HengRui Medicine Co., Ltd.	P1/2	CC (40)
hs-10365 Neoplasm	Jiangsu Hansoh Pharmaceutical Co., Ltd.	P1/2	CC (40)
ibi130 Neoplasm	Innovent Biologics (Suzhou) Co. Ltd.	P1/2	CC (40)
ibi3004 Neoplasm	Innovent Biologics (Suzhou) Co. Ltd.	P1/2	CC (40)
ibi3005 Neoplasm	Innovent Biologics (Suzhou) Co. Ltd.	P1/2	CC (40)

Showing 401 to 450 of 889 assets

PreviousPage 9 of 18Next